View More View Less
  • 1 Debreceni Egyetem ÁOK, 4032 Debrecen, Nagyerdei krt. 98.
  • 2 Debreceni Egyetem ÁOK, Debrecen
Open access

If the inline PDF is not rendering correctly, you can download the PDF file here.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Lenartova A, Randen U, Johannesen TB, et al. Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway. Cancer Epidemiol. 2019; 60: 128–133.

  • 2

    Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood 2018; 131: 2761 LP – 2772.

  • 3

    Kanagal-Shamanna R, Jain P, Patel KP, et al. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 2019; 125: 559–574.

  • 4

    Innocenti I, Rossi D, Trap? G, et al. Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. Hematol Oncol. 2018; 36: 600–603.

  • 5

    Guerrero-Hernandez M, Matas-Cespedes A, Serrat N, et al. Idelalisib interferes with the crosstalk of follicular lymphoma and its immune microenvironment and potentiates the activity of ABT-199. Blood. 2017; 130: 2813 LP – 2813.

  • 6

    Pham LV, Huang S, Zhang H, et al. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res. 2018; 24: 3967 LP – 3980.